Fiesto

Quick links to important sections

Fiesto

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fiesto

Understanding Fiesto

Fiesto is a therapeutic medication primarily indicated for the management of specific chronic conditions. It belongs to a class of drugs designed to interact with targeted biological pathways to alleviate symptoms and improve the overall physiological stability of patients.

Mechanism and Purpose

The primary function of Fiesto is to assist in the regulation of internal processes that have become imbalanced due to underlying health issues. By targeting specific receptors or enzymes, the medication works to maintain more consistent biological levels, which may help in reducing the frequency and intensity of symptomatic episodes.

Clinical Application

Fiesto is typically used in long-term treatment plans. It is designed for individuals who require ongoing support to manage their condition effectively. The medication is formulated to provide a steady therapeutic effect over time, rather than acting as a rapid-relief solution.

Patient Considerations

When considering Fiesto as part of a healthcare regimen, it is important to understand its role as a supportive tool in a broader clinical strategy. Its effectiveness is often monitored through regular assessments to ensure it aligns with the patient's specific health goals and physiological needs.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Fiesto?

Official Adverse Reactions and Safety Profile

The safety profile of Fiesto (fluoxetine) is derived from official regulatory documentation, which classifies possible side effects based on system-organ classes and frequency of occurrence in clinical use. Adverse reactions are grouped by the system of the body affected and their reported frequency, consistent with major international government health authorities.

Effects classified as very common (which may affect more than 1 in 10 people) typically involve disturbances in the nervous system, such as headache and insomnia, as well as gastrointestinal conditions like nausea and diarrhea. Fatigue is also frequently cited as a very common event.

Adverse reactions classified as common (affecting up to 1 in 10 people) include additional psychiatric symptoms such as anxiety, agitation, and decreased libido. Further common effects involve decreased appetite, dizziness, tremor, and dry mouth.

Serious Safety Considerations

Official regulatory documents highlight the potential for serious, though less frequent, adverse reactions. The development of Serotonin Syndrome is a key safety concern, particularly when used with other serotonergic agents. The risk of serious cutaneous reactions, such as Stevens-Johnson syndrome, and the potential for abnormal bleeding (e.g., gastrointestinal hemorrhage) are also explicitly documented in official labeling.

Population and Time-Related Safety Patterns

Certain safety patterns are noted to be specific to particular populations or treatment timing. Many side effects, including gastrointestinal disturbances, may be more frequently observed at the start of treatment or following a dose increase. Safety surveillance indicates that the risk of suicidality is a safety concern in pediatric and young adult patients, often noted during the initial phase of therapy and dose adjustments. Furthermore, there is an increased reporting of hyponatremia (low sodium levels) in older adults, and its clearance is reduced in patients with hepatic impairment.

Overdose and Emergency Response

The official regulatory documentation for Fiesto outlines specific clinical manifestations and mandated actions in the event of an overdose. Documented overdose presentations commonly include central nervous system effects such as drowsiness, tremor, and seizures, alongside autonomic disturbances like tachycardia and gastrointestinal symptoms like nausea and vomiting.

A Fiesto overdose is officially classified as potentially leading to life-threatening outcomes. These severe manifestations include Serotonin Syndrome, a condition characterized by rapid changes in mental status and neuromuscular and autonomic abnormalities. Furthermore, the risk of QT Prolongation and Ventricular Arrhythmia, specifically Torsades de Pointes, is documented, highlighting a critical cardiovascular risk. Coma is also recognized as a possible extreme outcome.

Since no specific antidote is known, regulatory bodies require that patients immediately seek medical attention or contact emergency services if an overdose is suspected or if any severe symptoms appear. Management is strictly symptomatic and supportive. Official procedures described for overdose management include the use of activated charcoal for GI decontamination and administration of benzodiazepines to control agitation or seizures. Due to cardiovascular risks, serial ECG monitoring is mandated to assess for signs of cardiotoxicity. A specific consideration exists for patients with hepatic impairment, as reduced liver function may increase systemic exposure to the drug, thereby raising the risk of overdose toxicity.

Therapeutic Uses of Fiesto

Fiesto is commonly used to help manage symptoms that interfere with daily functioning. It is relevant across domains where short-term symptomatic assistance or long-term management is utilized as part of symptomatic management.

The medication is commonly used to address conditions presenting with disruptive symptom manifestations, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, Panic Disorder (with or without agoraphobia), and Premenstrual Dysphoric Disorder (PMDD). It is also applied in scenarios requiring additional management of discomfort, such as in cases of Treatment Resistant Depression (TRD) or acute depressive episodes in Bipolar I Disorder (when used adjunctive).

It is relevant for easing the intensity of symptom clusters such as persistent low mood, overwhelming sadness, intrusive thoughts, compulsive behaviors, and cyclical tension. This application offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability.


Quick Fact: Assistance with Intrusive Thoughts Fiesto is relevant for managing the intensity of symptoms like unwanted obsessions and anxiety-driven compulsive rituals, contributing to easing the overall symptom load during symptomatic periods.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed

Eligibility and Restrictions for Use

Fiesto (Fluoxetine) eligibility is determined by specific regulatory criteria concerning age, concurrent medication use, underlying conditions, and reproductive status. All use must align with official, government-approved labeling.

Classification Eligibility Rule (Official Regulatory Statement)
Absolute Contraindications Prohibited for use in patients with known hypersensitivity to fluoxetine. Must not be used concurrently with MAOIs, Pimozide, or Thioridazine due to the risk of serious interaction.
Age-Related Eligibility Approved for adults (18+), adolescents 8 years and older for Major Depressive Disorder, and 7 years and older for Obsessive-Compulsive Disorder. Use in children below these ages is not established.
Conditional Use Patients with hepatic impairment (e.g., cirrhosis) require a lower or less frequent dosage. Renal impairment typically requires no adjustment. Use with caution is advised for patients with a history of seizures or risk factors for QT prolongation (e.g., heart conditions).
Reproductive Status Pregnancy: Should be used only if the potential benefit justifies the potential risk to the fetus. Lactation: Breastfeeding is not recommended by some health authorities.

These official statements define who is permitted, restricted, or prohibited from using the medicine, strictly according to regulatory standards.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The therapeutic effect and safety profile of Fiesto may be altered when taken simultaneously with certain other medications, due to drug-drug interactions that are primarily pharmacokinetic or pharmacodynamic in nature.

Pharmacokinetic Interactions: CYP Enzyme System

Fiesto's metabolism involves specific cytochrome P450 (CYP) enzymes, particularly CYP3A4. Therefore, co-administration with other products that significantly affect this enzyme can change the concentration of Fiesto in the bloodstream.

  • Strong CYP3A4 Inhibitors: Medicines such as certain antifungal agents (e.g., ketoconazole) or specific antibiotics (e.g., clarithromycin) can substantially increase Fiesto exposure. This may necessitate a lower dose of Fiesto to mitigate the risk of adverse effects.
  • Strong CYP3A4 Inducers: Conversely, medicines such as rifampin or certain anticonvulsants can decrease Fiesto’s concentration, potentially reducing its clinical effectiveness.

Pharmacodynamic Interactions: Anticholinergic Agents

Fiesto itself possesses anticholinergic properties. Concurrent use with other drugs that share this effect, such as certain antihistamines, tricyclic antidepressants, or other antimuscarinic drugs, may amplify side effects. This combination can increase the frequency or severity of effects like dry mouth, constipation, or urinary retention.

Other Interactions

In clinical studies, Fiesto did not exhibit clinically significant pharmacokinetic changes on medications like oral contraceptives containing ethinyl estradiol and levonorgestrel. Additionally, no significant effect on the blood thinning activity of warfarin has been observed. It is essential to provide a comprehensive list of all co-administered products, including herbal and non-prescription supplements, to a healthcare professional for a complete interaction assessment.

Mechanism of Action

How Fiesto Works: Mechanism of Action

Fiesto, a pro-drug, is rapidly converted into its active metabolite, 5-hydroxymethyl-tolterodine (5-HMT), via non-specific plasma esterase activity. This active metabolite exerts its pharmacologic effect by acting as a competitive antagonist at cholinergic muscarinic receptors. Fiesto demonstrates selectivity for the M2 and M3 receptor subtypes expressed on the bladder detrusor muscle.

Antagonism at these receptors prevents the neurotransmitter acetylcholine from binding and initiating the intracellular signaling cascade that mediates smooth muscle contraction. This molecular action directly modulates the excitatory input to the detrusor myocyte, leading to a decrease in detrusor pressure and reduced smooth muscle contractility. The resulting system-level physiological modulation is an increase in the volume required to elicit the micturition reflex and a decreased frequency of spontaneous calcium release events in the detrusor cell, altering the transduction of signals driven by cholinergic patterns in the lower urinary tract.

Dosage and Administration Information

How Fiesto is Used: Official Administration Guidelines

Fiesto (fluoxetine) is administered orally and is available in multiple formulations, including capsules, tablets, and an oral solution. The specific way this medicine is used—including dosage, frequency, and duration—follows established protocols.

Dosage and Frequency Patterns

The standard frequency for Fiesto is once daily, typically administered in the morning. The medicine may be taken with or without food, as ingestion does not significantly affect its absorption. Doses exceeding 20 mg per day may sometimes be split into a morning and noon dose.

Indication (Adult) Typical Starting Dose Maintenance Dose Range
Major Depressive Disorder (MDD) 20 mg once daily 20 mg to 60 mg daily
Obsessive-Compulsive Disorder (OCD) 20 mg once daily 20 mg to 60 mg daily
Bulimia Nervosa N/A Fixed dose of 60 mg daily

For most conditions, the maximum daily allowance is 80 mg. Certain formulations, such as the 90 mg delayed-release capsule, are intended for once weekly administration and require a specific 7-day interval when converting from a daily regimen.

Procedural and Population Adjustments

Due to the medicine's long presence in the body, dosage adjustments (titration) are generally made in gradual steps, often after several weeks to assess the full response. For patients with hepatic impairment, a lower or less frequent dose (such as 20 mg every other day) is advised. Dosing for older adults typically begins at the low end of the range, with a suggested limit not exceeding 40 mg daily in many cases. The oral solution requires precise measurement using the calibrated device provided. If a daily dose is missed, it is standard practice to take the next dose at the regular scheduled time without doubling the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fiesto

This overview provides a patient-friendly summary of the official research structure for Fiesto (fluoxetine), focusing on the types of studies conducted and what remains uncertain in the evidence landscape, while strictly avoiding clinical advice or safety information. Research findings describe group patterns, not personal outcomes.


Research Evidence for Mood and Obsessive-Compulsive Disorders

Research examined Fiesto within conditions characterized by functional limitations. The evidence base includes studies designed to monitor changes in symptom intensity or variability over defined time intervals.

Research for Major Depressive Disorder (MDD): Fiesto was studied for both the short-term evaluation of symptoms and the longer-term follow-up of symptom patterns. Researchers utilized short-term Randomized Controlled Trials (RCTs) to assess how symptoms evolved, with outcomes related to systemic or functional imbalance being tracked using standardized rating scales, typically over periods of 8 to 12 weeks. Studies monitored patterns related to the continuous observation of symptoms in some populations. However, the majority of research exploring short-term symptom changes have limited follow-up durations, meaning there is limited information for long-term outcomes regarding sustained functional status outside of specific continuation trials.

Research for Obsessive-Compulsive Disorder (OCD): Research examined Fiesto in conditions presenting with cycles of stability and flare-ups. Randomized Controlled Trials were conducted, primarily observing responses over time, typically 10 to 13 weeks. Studies monitored the severity of obsessive and compulsive symptoms using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Outcomes were measured in relation to different dose levels. Data for certain groups remain insufficient, and research focusing on functional remission, rather than just symptom score tracking, is more limited.


Studies in Special Populations and Adjunctive Use

Research has also explored the use of Fiesto in specific subgroups. In pediatric patients (children and adolescents), Fiesto was evaluated in trials for both MDD (ages 8 and older) and OCD (ages 7 and older). Studies monitored symptom intensity, but variability is noted across studies, and some scientific analyses describe that the measured differences in symptom scores were smaller or less pronounced compared to findings reported in adults.

Fiesto was also studied for adjunctive use in managing acute depressive episodes associated with Bipolar I Disorder or in Treatment Resistant Depression (TRD). These trials examined Fiesto only in combination with another specific medication. Therefore, the findings describe group patterns and results apply only to the populations studied using this specific combined regimen, providing limited information about Fiesto monotherapy in these complex contexts.


What Remains Uncertain in the Research Landscape

A primary limitation is that follow-up durations were limited across many acute trials. Additionally, data for certain groups remain insufficient, particularly in complex conditions where evidence is tied to a combination therapy. Research also describes where variability is noted across studies, such as in pediatric populations. Findings describe group patterns, and research does not determine whether an individual will respond similarly, reflecting the specific conditions under which the studies were conducted.

Key Studies & References

  1. Fluoxetine FDA Prescribing Information (Label) for Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa, and Panic Disorder
  2. NICE Guideline [NG222]: Depression in adults: treatment and management

Frequently Asked Questions (FAQ)

Common questions about Fiesto (FAQ)


Q: Is Fiesto similar to other drugs like [Name of Competitor Drug]? / What is the difference between Fiesto and a drug that treats the same thing but works differently?

Fiesto is classified by regulatory authorities as a Selective Serotonin Reuptake Inhibitor (SSRI). This classification describes its core pharmacological action, which is to regulate the availability of the neurotransmitter serotonin in the brain. Other medicines that share this specific mechanism are in the same class, while drugs that work differently target other chemical pathways.


Q: Is it normal to feel tired after starting Fiesto?

Fatigue (tiredness) is documented in official labeling as a very common adverse event. According to regulatory sources, many side effects, including fatigue, are often more frequently observed at the start of treatment or following an increase in dose.


Q: Is it safe to drink alcohol in moderation while taking Fiesto?

Official guidance suggests that alcohol consumption should be avoided while taking Fiesto. This is because alcohol may amplify certain effects of the medicine, which could potentially increase the risk of adverse events.


Q: What are the signs of a severe allergic reaction to Fiesto?

Signs of a serious allergic reaction documented in official patient information include swelling of the face, tongue, eyes, or mouth, the development of hives or a spreading rash, or trouble breathing. If any of these signs occur, official guidance indicates immediate emergency medical attention should be sought.


Q: How does Fiesto affect my mood?

Fiesto is intended to help restore functional equilibrium in the brain’s communication system, supporting recovery from persistent emotional distress and disruptions in mood regulation. Official patient information describes potential improvements in sleep, energy, and appetite as the medicine begins to work, which may precede the full therapeutic response.


Q: Do research studies show that Fiesto helps with long-term quality of life?

Official research evidence describes that while studies assessed short-term symptom changes, there is limited information for long-term outcomes regarding sustained functional status or quality of life. This is typical outside of specific continuation trials which have limited scope.


Q: What are the major reasons someone might have to stop taking Fiesto?

Official documents list absolute prohibitions against using Fiesto with certain other drugs, such as MAOIs or Thioridazine. Reasons for potential discontinuation mentioned in safety warnings include the development of severe adverse reactions such as Serotonin Syndrome or serious cutaneous reactions.


Q: Can Fiesto cause stomach upset or digestive problems?

Yes, digestive problems are commonly reported. According to official adverse reaction lists, these include nausea and diarrhea (listed as very common). Other digestive effects like dry mouth and constipation have also been noted in official product information.


Q: Is Fiesto used for anything besides the main condition?

Yes, Fiesto is officially indicated by regulatory authorities for conditions beyond its primary uses. These include the treatment of Bulimia Nervosa and Pre-menstrual Dysphoric Disorder (PMDD) in adults.


Q: How quickly does Fiesto start to work?

Official information indicates that the full therapeutic effect of Fiesto may be delayed until after at least four to five weeks of treatment. Changes in dose may take several weeks to be fully reflected in the body due to the medicine's long presence in the system.


Q: How long does one dose of Fiesto last in your system?

Fiesto is known for having a long presence in the body due to its unique chemical properties. The elimination half-life of Fiesto is approximately four to six days, and its active form has an even longer half-life. This prolonged presence means the active substance may remain in the body for weeks after dosing is stopped.


Q: Can Fiesto be taken long-term?

Fiesto has regulatory approval for both acute use and maintenance treatment of its indicated conditions. For certain uses, such as PMDD, official documents specify that initial treatment is limited to 6 months, after which the need for continued therapy is subject to re-evaluation by a healthcare professional.


Q: Does Fiesto cause weight gain or loss?

Changes in appetite and weight have been reported in clinical trials and are included in official documentation. In studies, both decreased appetite and weight loss were commonly reported, as well as weight gain (defined as a ge 7% increase) in some patients.


Q: Can I take Fiesto with my blood pressure medication?

Regulatory information notes that serious drug interactions, such as Serotonin Syndrome, are associated with the risk of rapid changes in heart rate or blood pressure. Due to this potential for cardiovascular effects, co-administration with blood pressure medication is subject to specific assessment by a healthcare professional.


Q: Are there any foods or drinks I need to avoid while on Fiesto?

While the medicine may be taken with or without food, official warnings indicate a moderate interaction risk with alcohol, and its consumption is not recommended. The medicine's metabolic pathway also suggests that strong inhibitors of the CYP3A4 enzyme, such as grapefruit, may alter its concentration in the body.


Q: What is the official success rate or effectiveness theme reported for Fiesto?

Official research does not typically report a single, overall 'success rate.' Instead, studies tracked effectiveness by measuring changes in symptom intensity or variability over defined periods using standardized rating scales, such as the Y-BOCS for OCD.


Q: Does Fiesto affect my ability to drive or operate machinery?

Regulatory warnings explicitly state Fiesto has the potential to impair judgment, thinking, and motor skills. Patients are advised in official documentation to use caution when operating machinery, including driving.


Q: Is it possible to take too much Fiesto?

Yes, an overdose is possible. Symptoms of an overdose documented in official drug information may include agitation, confusion, seizures, or a rapid, irregular heartbeat. Official guidance indicates that such events necessitate immediate emergency medical attention.


Q: What if I'm already taking a multivitamin with Fiesto?

According to official regulatory databases, no significant direct interactions were found between Fiesto and common multivitamin products. Regulatory information emphasizes that the patient should provide a comprehensive list of all co-administered products.


Q: How often are the side effects of Fiesto reported?

The official frequency of side effects is captured and monitored through national reporting schemes. Patients and healthcare professionals can report any suspected side effects to a national system, such as the Yellow Card Scheme (UK) or the MedWatch system (US), for official safety monitoring.


Q: Does Fiesto change the results of blood work?

Fiesto is associated with the potential for changes in certain lab values documented in official safety information. There is a specific risk for low sodium levels (hyponatremia). It may also alter the results of tests related to blood clotting or blood glucose levels.


Q: What type of healthcare professional usually prescribes Fiesto?

Fiesto is a prescription-only medicine and requires a legal prescription from an authorized prescriber. Regulatory guidance emphasizes that treatment and supervision is to be overseen by a physician or another healthcare professional authorized to prescribe the drug.


Q: Is Fiesto a new drug or has it been around for a while?

The active ingredient in Fiesto, fluoxetine, has been available for clinical use for a number of years. This long history has allowed for the establishment of multiple dosage forms and an extensive official safety and efficacy evidence base.


Q: What is the benefit of Fiesto compared to just managing the symptoms?

The defined therapeutic purpose of Fiesto is to address underlying disruptions in neurotransmission and support recovery from emotional distress. Symptom management, by contrast, typically addresses only the observable distress without targeting the potential systemic imbalance described in the medicine’s mechanism of action.


Q: Why do official documents mention 'unknown' side effects for Fiesto?

When a side effect is listed with an unknown frequency, it means the reaction was observed during post-marketing surveillance (after the medicine was approved). The available data are insufficient to determine its exact frequency in the population, but it is included as a safety precaution.


Q: Does Fiesto have a black box warning?

Yes, the FDA requires a Boxed Warning for Fiesto, as it does for all antidepressants. This warning concerns the potential increased risk of suicidal thoughts or actions in pediatric and young adult patients, particularly during the initial phase of treatment or following dose changes.


Q: Is Fiesto safe to take with other common over-the-counter cold medicines?

Official warnings advise caution with many common over-the-counter cold medicines, especially those containing dextromethorphan (a cough suppressant). Co-administration with these products may increase the risk of a serious interaction known as Serotonin Syndrome.


How should Fiesto be stored and disposed of?

How to Store and Dispose of Fiesto

The storage and disposal requirements for Fiesto (fluoxetine) are strictly defined by regulatory documents to maintain product quality and safety.


Storage Conditions

  • Temperature: Store at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C.
  • Protection: The medicine must be protected from light and moisture, and stored in its original container.
  • Handling: Avoid excessive heat and do not freeze the product.
  • Child Safety: It is mandatory to keep Fiesto out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

  • Disposal Method: Unused or expired Fiesto should be disposed of via drug take-back programs or by an authorized collector as the primary method.
  • Household Disposal: If a take-back program is unavailable, the product must be mixed with an undesirable substance (such as dirt or coffee grounds) and sealed in a container before being placed in the household trash.
  • Wastewater: The official guidance instructs that Fiesto must not be thrown away via wastewater (flushed down the toilet).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fiesto found in:

A-Z Index: